Arena Pharmaceuticals Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 448

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $6.7B

Arena Pharmaceuticals General Information

Description

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 6154 Nancy Ridge Drive
  • San Diego, CA 92121
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 6154 Nancy Ridge Drive
  • San Diego, CA 92121
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arena Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 11-Mar-2022 $6.7B Completed Generating Revenue
9. Secondary Transaction - Open Market Completed Generating Revenue
8. Secondary Transaction - Open Market Completed Profitable
7. PIPE 01-May-2012 Completed Profitable
6. PIPE 29-Mar-2011 Completed Profitable
5. General Corporate Purpose 17-Jun-2009 Completed Profitable
4. PIPE 24-Dec-2003 Completed Profitable
3. IPO 28-Jul-2000 Completed Profitable
2. Grant 19-Jan-2000 $106K $17M Completed Startup
1. Later Stage VC (Series D) 22-Feb-1999 $17M $17M Completed Startup
To view Arena Pharmaceuticals’s complete valuation and funding history, request access »

Arena Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally d
Drug Discovery
San Diego, CA
448 As of 2021

Tokyo, Japan
 

Foster City, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Arena Pharmaceuticals Competitors (34)

One of Arena Pharmaceuticals’s 34 competitors is Takeda Pharmaceutical, a Corporation company based in Tokyo, Japan.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Takeda Pharmaceutical Corporation Tokyo, Japan
Gilead Formerly VC-backed Foster City, CA
Neuro-Sys Accelerator/Incubator Backed Gardanne, France
Bristol-Myers Squibb Corporation Princeton, NJ
Mesoblast Corporation Melbourne, Australia
You’re viewing 5 of 34 competitors. Get the full list »

Arena Pharmaceuticals Patents

Arena Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260091039-A1 Hydrochloric acid salt of a 5-ht2c agonist Pending 01-Oct-2024
WO-2026075995-A1 Hydrochloric acid salt of a 5-ht2c agonist Pending 01-Oct-2024
WO-2026043678-A1 Bexicaserin for use in a method of treatment of seizure-induced sudden unexpected death in epilepsy Pending 23-Aug-2024
WO-2026025075-A1 Bexicaserin for use in the treatment and/or prevention of epileptic disorders in a child patient Pending 26-Jul-2024
US-20260048069-A1 Methods of treatment Pending 26-Jul-2024 A61K31/5517
To view Arena Pharmaceuticals’s complete patent history, request access »

Arena Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arena Pharmaceuticals Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Certara Corporation Minority
Deerfield Management Venture Capital Minority
Eaton Vance Asset Manager Minority
Frazier Healthcare Partners PE/Buyout Minority
Great Point Partners PE/Buyout Minority
You’re viewing 5 of 11 investors. Get the full list »

Arena Pharmaceuticals Investments & Acquisitions (5)

Arena Pharmaceuticals’s most recent deal was a Grant with Coral Genomics for . The deal was made on 01-Sep-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Coral Genomics 01-Sep-2021 Grant Biotechnology
Longboard Pharmaceuticals 28-Oct-2020 Early Stage VC Drug Discovery
Siegfried Holding (Pharmaceutical Final Dosage Forms Business) 09-Jan-2008 Merger/Acquisition Pharmaceuticals
TaiGen Biotechnology 01-Jul-2001 Early Stage VC Drug Discovery
Bunsen Rush Laboratories 01-Feb-2001 Merger/Acquisition Discovery Tools (Healthcare)
To view Arena Pharmaceuticals’s complete investments and acquisitions history, request access »

Arena Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

15.64 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Arena Pharmaceuticals’s complete esg history, request access »

Arena Pharmaceuticals FAQs

  • When was Arena Pharmaceuticals founded?

    Arena Pharmaceuticals was founded in 1997.

  • Where is Arena Pharmaceuticals headquartered?

    Arena Pharmaceuticals is headquartered in San Diego, CA.

  • What is the size of Arena Pharmaceuticals?

    Arena Pharmaceuticals has 448 total employees.

  • What industry is Arena Pharmaceuticals in?

    Arena Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Arena Pharmaceuticals a private or public company?

    Arena Pharmaceuticals is a Private company.

  • What is the current valuation of Arena Pharmaceuticals?

    The current valuation of Arena Pharmaceuticals is .

  • What is Arena Pharmaceuticals’s current revenue?

    The current revenue for Arena Pharmaceuticals is .

  • How much funding has Arena Pharmaceuticals raised over time?

    Arena Pharmaceuticals has raised $366M.

  • Who are Arena Pharmaceuticals’s investors?

    Certara, Deerfield Management, Eaton Vance, Frazier Healthcare Partners, and Great Point Partners are 5 of 11 investors who have invested in Arena Pharmaceuticals.

  • Who are Arena Pharmaceuticals’s competitors?

    Takeda Pharmaceutical, Gilead, Neuro-Sys, Bristol-Myers Squibb, and Mesoblast are some of the 34 competitors of Arena Pharmaceuticals.

  • When was Arena Pharmaceuticals acquired?

    Arena Pharmaceuticals was acquired on 11-Mar-2022.

  • Who acquired Arena Pharmaceuticals?

    Arena Pharmaceuticals was acquired by Pfizer.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process